A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.

Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85% ...

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...

Robert Crane, the founder of Bob’s Bikes for Needy Kids, passed away after a battle with prostate cancer, leaving behind a ...

A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...

A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes.

Prostate cancer is the most common cancer in Australian men, often detected through PSA blood tests. New guidelines suggest ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of ...

A new research paper was published in Volume 16 of Oncotarget on June 25, 2025, titled "Hypoxia induced lipid droplet ...

It's natural to have questions about a prostate exam. Here, a Tufts University chair of urology gently walks you through the ...